Accuray Showcases New Long-Term Data¹ on Benefits of 5 Session Radiotherapy Treatment for Men with Prostate Cancer at ESTRO 2025

Core Insights - Accuray Incorporated presented over 40 clinical studies at the ESTRO 2025 meeting, highlighting the effectiveness of its CyberKnife® System in treating prostate cancer at various stages [1][2] - The studies emphasize the system's precision and ability to treat high-risk and recurrent prostate cancer, promoting a non-invasive treatment option [1][2] - Accuray's symposium at the meeting attracted 350 healthcare professionals, focusing on advancements in genitourinary radiotherapy [3] Clinical Data and Outcomes - A retrospective analysis involving 262 men over 70 or with severe comorbidities showed favorable outcomes with CyberKnife SBRT, reporting low rates of acute and late urogenital and gastrointestinal toxicities [4] - An early trial on stereotactic salvage radiotherapy (SSRT) for prostate bed recurrence after prostatectomy indicated mild toxicity and a shorter treatment duration compared to standard approaches [5] Company Commitment and Innovation - Accuray is dedicated to advancing radiation therapy solutions, aiming to improve patient care and outcomes through continuous innovation [6]